Printer Friendly
The Free Library
14,599,653 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

LifeSpan BioSciences Enters into Agreement with Roche for Expanded DrugTarget(TM) Localization Database.


SEATTLE -- LifeSpan BioSciences, Inc., a leading antibody company specializing in immunohistochemistry and antibodies to drug target proteins, today announced a multi-year agreement with Roche for a subscription to LifeSpan's DrugTarget Database(TM).

Under the terms of the agreement, Roche Pharma will gain access to all the features of the CNS See Continuous net settlement.

CNS

See continuous net settlement (CNS).
 subset of the DrugTarget Database(TM). These include informatics on more than 3,400 genes, 886 comprehensive immunohistochemistry (IHC IHC Immunohistochemistry
IHC Intermountain Health Care
IHC Inner Hair Cells
IHC International Harvester Company
IHC Internet Healthcare Coalition
IHC Indian Head Cent
IHC Interactive Health Communication
IHC International Hurricane Center
) reports with localization Customizing software and documentation for a particular country. It includes the translation of menus and messages into the native spoken language as well as changes in the user interface to accommodate different alphabets and culture. See internationalization and l10n.  information on more than 450 potential drug targets selected by pharmaceutical company subscribers, and innovative search and analysis tools. LifeSpan continues to build the database by publishing localization data on an undisclosed number of additional protein targets each year.

"Roche's commitment to the DrugTarget Database(TM)consortium supports LifeSpan's vision of achieving a comprehensive human tissue localization resource for all therapeutically important proteins," said Joseph P. Brown, Ph.D., LifeSpan's Chief Executive Officer. "With current subscribers, LifeSpan expects to add over new 200 targets to the database. With the addition of new subscribers, we will substantially increase this number. The DrugTargetDatabase(TM) significantly enhances the ability of pharmaceutical companies to effectively identify and validate new targets."

The LifeSpan DrugTarget Database(TM) is LifeSpan's next-generation database following its successful GPCR GPCR Guanine Nucleotide-Binding Protein-Coupled Receptor
GPCR GTP-binding Protein-Coupled Receptor
 and NHR NHR National Honor Roll
NHR Next Hop Router
NHR Nationale Havenraad
NHR Natural Hazards Review
NHR National Handwriting Recognition
NHR Non Hierarchical Routing
 family databases. In addition to accessing previously generated data, subscribers to the DrugTarget Database nominate new targets that they consider to be of therapeutic relevance, regardless of gene family. Significant growth is expected in the Ion Channel ion channel
n.
See channel.
, Protein Kinase, and Transporter gene families, as well as many others. For each protein studied, LifeSpan will provide IHC localization information on 75 human normal and diseased tissues at the cellular level, often using custom generated antibodies. The DrugTarget Database(TM) has been further enhanced by using of additional methods to validate the antibodies, including Western blots and transfection transĀ·fecĀ·tion
n.
Infection of a bacterium or cell with DNA or RNA isolated from a bacteriophage or from an animal or a plant virus, resulting in replication of the complete virus.
 assays, and an expansion of existing data mining tools.

About LifeSpan BioSciences, Inc.

LifeSpan BioSciences, headquartered in Seattle, Washington, is a privately held company privately held company

A firm whose shares are held within a relatively small circle of owners and are not traded publicly.
 founded in 1995 that employs human tissues, specific antibodies and immunohistochemistry to identify and validate targets for its biotechnology and pharmaceutical company customers in Europe, Asia and North America. Products and services include more than 1,300 antibodies, custom IHC-validated antibody synthesis, IHC contract research services, custom tissue microarray (TMA TMA Turnaround Management Association
TMA Texas Medical Association
TMA Transportation Management Association
TMA Training and Management Assistance (a component of OHRD, which is a component of OWR)
TMA Tooling & Manufacturing Association
) construction for use in contract research studies, pathology and imaging services, monoclonal antibody cross-reactivity screening services, subscription access to comprehensive human tissue IHC localization profiles for 400+ Drug Targets, an expression focused informatics resource for 3,200 genes.

For additional information on LifeSpan BioSciences, please visit LifeSpan's web site at www.lsbio.com
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 30, 2007
Words:426
Previous Article:AVST and CIT Enter Strategic Relationship.(Company overview)
Next Article:Lombardi Business Process Management Suite Leads the Way in Financial Services Sector.
Topics:



Related Articles
LIFESPAN DATABASE HELPS IN DRUG DISCOVERY EFFORTS.(Company Business and Marketing)
CHANNEL PARTNERSHIP MARKETS MASTERCATALOG & DECYPHER.(Company Business and Marketing)
IGEN MUST PRODUCE DOCUMENTS ON EISAI RELATIONSHIP.
GENMAB/ROCHE ANNOUNCE BROAD ANTIBODY DEVELOPMENT COLLABORATION.
MAP OF WW PROTEIN DOMAIN HELPS TARGET HEALTH PROBLEMS.(Company Business and Marketing)
AXCELL/MUENSTER ALLIANCE TO RESEARCH PROTEIN INTERACTIONS.
CURATED DATA COVERS OVER 2,000 HUMAN GENES.(LifeSpan BioSciences' subscription DrugTarget Database)
ROCHE/GLYCART TO DISCOVER NEW THERAPEUTIC ANTIBODIES.
LifeSpan BioSciences Announces Agreement With Pfizer for Expanded DrugTarget(TM) Localization Database.
MBL International Acquires Antibody Business from LifeSpan BioSciences.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles